Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
L
Ladumor, Mayur K.
Merck & Co.
PII-023
-
PBPK MODEL DEVELOPMENT AND VALIDATION FOR ROSUVASTATIN: INTEGRATING IN VITRO, CLINICAL PHARMACOKINETIC, AND LIVER PET IMAGING DATA TO IMPROVE PREDICTIONS OF OATP1B- AND BCRP-MEDIATED DRUG-DRUG INTERACTIONS
Mayur K. Ladumor
Favorite
Le Merdy, Maxime
Simulations Plus, Inc.
PI-101
-
PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Maxime Le Merdy
Favorite
Le, An
University of Pittsburgh
PT-002
-
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
An Le
Favorite
PWI-001
-
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT
An Le
Favorite
Lee, Mark
Daiichi Sankyo
PI-062
-
CONCENTRATION-QTC ANALYSIS OF PATRITUMAB DERUXTECAN IN PATIENTS WITH HER3-EXPRESSING METASTATIC BREAST CANCER OR METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
Mark Lee
Favorite
Lee, seungri
Seoul National University College of Medicine
PII-121
-
PHARMACOKINETICS AND SAFETY OF NANOPARTICLE FENOFIBRATE (AD-104-A) IN RENAL IMPAIRMENT PATIENTS.
seungri Lee
Favorite
LEMAITRE, Florian
Rennes University Hospital, Rennes, France
PII-105
-
EFFECT OF P-GLYCOPROTEIN INHIBITION ON TWO TACROLIMUS FORMULATIONS: A RANDOMIZED, 4-SEQUENCE, CROSS-OVER, DRUG-DRUG INTERACTION STUDY
Florian LEMAITRE
Favorite
Le, Sunny
Biopharma Services
PII-013
-
EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS
Sunny Le
Favorite
Lennox, Ashley
Geron Corporation
PII-033
-
NO EFFECT OF IMMUNOGENICITY ON THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF THE NOVEL OLIGONUCLEOTIDE TELOMERASE INHIBITOR IMETELSTAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
Ashley Lennox
Favorite
Letscher, Emily
University of Minnesota
PI-105
-
EFFECT OF INDUCED HYPOGLYCEMIA ON OXIDATIVE STRESS IN HEALTHY VOLUNTEERS AND THE POTENTIAL APPLICATIONS OF N-ACETYLCYSTEINE
Emily Letscher
Favorite
Levi, Micha
Bill and Melinda Gates Medical Research Institute
PII-015
-
MODELING AND SIMULATION ANALYSIS TO SUPPORT DOSE SELECTION FOR MAM01, A NOVEL ANTI-CIRCUMSPOROZOITE PROTEIN MONOCLONAL ANTIBODY, IN UPCOMING TRIALS
Micha Levi
Favorite
Li, Dan
Merck
PII-084
-
POPULATION PHARMACOKINETIC ANALYSIS OF MK-5475 IN HEALTHY PARTICIPANTS AND PATIENTS WITH PULMONARY HYPERTENSION
Dan Li
Favorite
Li, Jing
Karmanos Cancer Institute
PI-097
-
MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS
Jing Li
Favorite
Li, Lang
The Ohio State University
PII-113
-
PHARMACOTHERAPY RESEARCH LANDSCAPE AND KNOWLEDGE GAP FOR OPIOIDS AMONG THE MATERNAL AND PEDIATRIC POPULATIONS
Lang Li
Favorite
Lim, Chay Ngee
Pfizer Inc
PI-110
-
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A SINGLE DOSE OF RIMEGEPANT IN CHILDREN (>=6 TO <12 YEARS OF AGE) WITH A HISTORY OF MIGRAINE
Chay Ngee Lim
Favorite
Li, Mengyao
Bicycle Therapeutics, Inc.
PII-090
-
POPULATION PK (POPPK) AND EXPOSURE-SAFETY (E-S) ANALYSIS OF BT5528, A BICYCLE TOXIN CONJUGATE (BTC®), IN PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH EPHA2 EXPRESSION.
Mengyao Li
Favorite
Li, Min
RemeGen Co., Ltd.
PI-028
-
CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS
Min Li
Favorite
Lim, SoHyeon
Seoul National University
PI-107
-
OPTIMIZING VANCOMYCIN DOSING REGIMENS FOR OBESE PATIENTS
SoHyeon Lim
Favorite
Li, Shuxia
The First Affiliated Hospital of Sun Yat-sen University
PI-112
-
ESTIMATION OF THE AREA UNDER THE CURVE OF MYCOPHENOLIC ACID CONCENTRATION IN CHINESE PEDIATRIC RENAL TRANSPLANT PATIENTS USING LIMITED SAMPLING METHOD.
Shuxia Li
Favorite
Liu, Can
Bristol Myers Squibb
PII-068
-
EXPOSURE-RESPONSE ANALYSES FOR EFFICACY AND SAFETY OF BMS-986365, A DUAL ANDROGEN RECEPTOR LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Can Liu
Favorite
Liu, Han
Uppsala University
PII-031
-
INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS
Han Liu
Favorite
Li, Yang
Merck & Co., Inc.
E-002
-
REDUCTION IN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OBSERVED WITH DORAVIRINE (DOR) IS CAUSED BY INHIBITION OF ORGANIC CATION TRANSPORTER 2 (OCT2)
Yang Li
Favorite
Li, Ziran
University of California, San Francisco
OAII-003
-
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Ziran Li
Favorite
PI-089
-
POPULATION PHARMACOKINETICS OF PYRAZINAMIDE FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS
Ziran Li
Favorite
PT-019
-
APPLYING ARTIFICIAL INTELLIGENCE-BASED DIGITAL TWINS IN TUBERCULOSIS CLINICAL TRIALS
Ziran Li
Favorite
Lyu, Xintian
University of Minnesota
PII-057
-
AN AUTOMATED COMPARISON PLATFORM FOR INFORMED DRUG LABELING DECISIONS: WEIGHT-BASED DOSING VS. WEIGHT-BANDED DOSING.
Xintian Lyu
Favorite
